novo nordisk glp-1 patent litigation Novo's Suit Against Hims Takes Aim at Compounding The Growing Market for Weight

This procedure ensured that individual patients could not be directly or indirectly identified, safeguarding patient privacy in compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations

Currently, no reliable estimates of the compounding market for these drugs exist

Major Indian drugmakers, including Sun Pharma, Dr Reddys, Zydus, Glenmark and Natco, have rushed to launch their own versions

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells